April 12, 2016

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

Structured PICO

Does Simoa provide better sensitivity than ELISA or ECL for quantifying neurofilament light chain in blood samples?

Intervention

Simoa technology for quantifying neurofilament light chain (NfL) in serum

Comparator

ELISA and electrochemiluminescence (ECL) immunoassay

Outcome

Assay sensitivity and correlation with CSF NfL testsurrogate

Simoa is a highly sensitive technology for quantifying serum neurofilament light chain, outperforming ELISA and ECL assays, and correlating well with CSF levels.

Abstract

We found Simoa to be more sensitive than ELISA or the ECL assay. Our results support the feasibility of quantifying NfL in serum; the results correlate with the more-established CSF NfL test. The highly sensitive Simoa technology deserves further studies in larger patient cohorts to clarify whether serum NfL could be used in the future to measure disease severity and determine prognosis or response to treatment interventions in neurological diseases.

Bookmark

Cite This Study

Kühle et al. (Tue,) studied this question.

synapsesocial.com/papers/69d8df692c87b79b92d17f1d https://doi.org/https://doi.org/10.1515/cclm-2015-1195

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark